Twice-daily pth1–34 is superior to once-daily therapy in children with hypoparathyroidism

Access through your institution Buy or subscribe Winer KK _ et al_. (2008) Effects of once versus twice-daily parathyroid hormone1-34 therapy in children with hypoparathyroidism. _J Clin

Endocrinol_ [doi:10.1210/jc.2007-2552] Conventional therapy for patients with hypoparathyroidism comprises vitamin D3 and calcium supplementation, which normalizes serum but not urinary

calcium levels. Previous studies suggested that twice-daily administration of synthetic, truncated, human parathyroid hormone (PTH1–34) maintains normal serum and urinary calcium levels in

adults with hypoparathyroidism. Winer and colleagues performed a randomized, crossover study to compare the efficacy of once-daily and twice-daily PTH1–34 in children with

hypoparathyroidism. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues

and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local

taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support RIGHTS AND PERMISSIONS

Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Twice-daily PTH1–34 is superior to once-daily therapy in children with hypoparathyroidism. _Nat Rev Endocrinol_ 4, 475–476

(2008). https://doi.org/10.1038/ncpendmet0907 Download citation * Issue Date: September 2008 * DOI: https://doi.org/10.1038/ncpendmet0907 SHARE THIS ARTICLE Anyone you share the following

link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature

SharedIt content-sharing initiative